oki-219
·Code: OKI-219
oki-219: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| OnKure Therapeutics, Inc. (OKUR) | Phase 1 |
Clinical Trials (1)
PIKture-01: First-in-Human Study of the PI3KαH1047R Mutant-Selective Inhibitor OKI-219 as Monotherapy in Participants With Advanced Solid Tumors and as Part of Combination Therapy in Participants With Advanced Breast Cancer
Frequently asked questions
Who is developing oki-219?
oki-219 is being developed by OnKure Therapeutics, Inc..
How many clinical trials involve oki-219?
BioSniper tracks 1 clinical trial involving oki-219.
Get deeper analysis on oki-219
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis